{
    "clinical_study": {
        "@rank": "109200", 
        "arm_group": [
            {
                "arm_group_label": "Red light dose (PDT) 75 J/cm2", 
                "arm_group_type": "Other", 
                "description": "Subjects in Cohort 1 will receive active and vehicle solution followed by a red light dose of 75 J/cm2 at 25 mW/cm2"
            }, 
            {
                "arm_group_label": "Red Light (PDT) 150 J/cm2", 
                "arm_group_type": "Other", 
                "description": "Subjects in Cohort 2 will receive active and vehicle solution followed by a red light dose of 150 J/cm2 at 40 mW/cm2"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is assess the safety and tolerability of lemuteporfin topical\n      solution (LTS) with exposure to red light (PDT), when applied to the backs of healthy\n      volunteers."
        }, 
        "brief_title": "Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Acne Vulgaris", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, safety study in healthy volunteers.  Two cohorts, of 6 subjects each,\n      will be enrolled (total subjects = 12).  Each subject will have test areas identified on the\n      back and receive a single LTS, vehicle solution and red light (PDT) applied to the test\n      areas on the back.  Subjects will be followed for safety at study visits occurring on Day 1\n      (baseline and treatment), Day 2, and Day 7."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy adults 18 years of age or older\n\n          2. Fitzpatrick skin types I-IV\n\n        Exclusion Criteria:\n\n          1. Current pregnancy or lactation.\n\n          2. Presence of severe facial acne, acne fulminans or conglobata, or nodulocystic acne.\n\n          3. Poor skin condition on the back, including erythema, dryness, sunburn, dermatological\n             malignancies, infections, cuts, abrasions, tattoo, excess of hair or any other skin\n             condition\n\n          4. Subjects who have used any agents known to produce significant photosensitivity\n             reactions (tetracyclines, phenothiazines, trimethoprim, etc.) within 2 weeks of Day 1\n             or 5 half-lives, whichever is longer.\n\n          5. Subjects who have used any medicated topical therapy on the back within 3 days of Day\n             1.\n\n          6. Chronic treatment with low dose aspirin, a non-steroidal anti inflammatory drug\n             (NSAID), or an anticoagulant regimen such as warfarin (Coumadin).\n\n          7. Abnormal findings on screening ECG deemed clinically significant by the Investigator.\n\n          8. Active participation in an experimental therapy study or experimental therapy within\n             30 days of Day 1.\n\n          9. Screening clinical chemistry or hematology laboratory value that is considered\n             clinically significant, in the opinion of the Investigator.\n\n         10. Subjects who are a poor medical risk because of other systemic diseases or active\n             uncontrolled infections."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830764", 
            "org_study_id": "LTS-ACN06"
        }, 
        "intervention": {
            "arm_group_label": [
                "Red light dose (PDT) 75 J/cm2", 
                "Red Light (PDT) 150 J/cm2"
            ], 
            "description": "LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2)", 
            "intervention_name": "Red Light (PDT)", 
            "intervention_type": "Drug", 
            "other_name": "LTS-PDT"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Paramus", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07652"
                }, 
                "name": "TKL Research Inc (Research Clinics Division)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label Safety and Tolerability Study of LTS 0.3% With Red Light Applied to the Backs of Healthy Volunteers", 
        "overall_official": {
            "affiliation": "TKL Research Inc (Research Clinics Division)", 
            "last_name": "Jonathan S Dosik, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Adverse events and local tolerability assessed at pre and immediately post treatment, at Day 1 and Day 7 following treatment.", 
            "measure": "Adverse Events", 
            "safety_issue": "No", 
            "time_frame": "1 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830764"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Dermira, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dermira, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}